Catalyst Brief

← Calendar

Readoutin 14d

Biohaven Therapeutics Ltd. — BHV-7000

Phase 3 primary completion: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy.

Date
Dec 2026
Type
Readout
Indication
Focal Epilepsy

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.